ATE525372T1 - Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen - Google Patents

Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen

Info

Publication number
ATE525372T1
ATE525372T1 AT06809149T AT06809149T ATE525372T1 AT E525372 T1 ATE525372 T1 AT E525372T1 AT 06809149 T AT06809149 T AT 06809149T AT 06809149 T AT06809149 T AT 06809149T AT E525372 T1 ATE525372 T1 AT E525372T1
Authority
AT
Austria
Prior art keywords
pain
treatment
sodium channel
channel modulators
pyrazine derivatives
Prior art date
Application number
AT06809149T
Other languages
English (en)
Inventor
Karl Gibson
Cedric Poinsard
Melanie Glossop
Mark KEMP
Stephen Denton
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of ATE525372T1 publication Critical patent/ATE525372T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT06809149T 2005-11-04 2006-10-23 Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen ATE525372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73366205P 2005-11-04 2005-11-04
PCT/IB2006/003055 WO2007052123A2 (en) 2005-11-04 2006-10-23 Pyrazine derivatives as sodium channel modulators for the treatment of pain

Publications (1)

Publication Number Publication Date
ATE525372T1 true ATE525372T1 (de) 2011-10-15

Family

ID=37890558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06809149T ATE525372T1 (de) 2005-11-04 2006-10-23 Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen

Country Status (27)

Country Link
US (1) US7572797B2 (de)
EP (1) EP1945630B1 (de)
JP (1) JP2009514937A (de)
KR (1) KR20080066073A (de)
CN (1) CN101356169A (de)
AP (1) AP2008004468A0 (de)
AR (1) AR057855A1 (de)
AT (1) ATE525372T1 (de)
AU (1) AU2006310215A1 (de)
BR (1) BRPI0618129A2 (de)
CA (1) CA2624621C (de)
CR (1) CR9954A (de)
DO (1) DOP2006000243A (de)
EA (1) EA200801011A1 (de)
EC (1) ECSP088412A (de)
ES (1) ES2371932T3 (de)
GT (1) GT200600475A (de)
IL (1) IL191059A0 (de)
MA (1) MA29926B1 (de)
NL (1) NL2000284C2 (de)
NO (1) NO20082496L (de)
PE (1) PE20070715A1 (de)
TN (1) TNSN08196A1 (de)
TW (1) TW200804353A (de)
UY (1) UY29893A1 (de)
WO (1) WO2007052123A2 (de)
ZA (1) ZA200803671B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (de) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba und dessen derivate zur schmerzbehandlung
EP1741708A1 (de) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit ungesättigtem oder zyklischem Linker, und deren Verwendung als Pharmaka
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US20100227872A1 (en) * 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
WO2009026434A1 (en) * 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
JPWO2009101917A1 (ja) 2008-02-13 2011-06-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 ビシクロアミン誘導体
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) * 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
ES2645984T3 (es) * 2012-04-25 2017-12-11 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de TTX-S
EP3495359A1 (de) 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap-modulatoren
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
CA2960274A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
TWI771269B (zh) 2015-02-27 2022-07-21 美商鈣系醫藥公司 胰腺炎治療
CA2995094A1 (en) * 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
CA3172249A1 (en) 2020-03-20 2021-09-23 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
JP7791898B2 (ja) 2020-11-13 2025-12-24 カルシメディカ，インク． Ｃｒａｃチャネル阻害剤の合成の改善

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA26473A1 (fr) * 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.
DE60234269D1 (de) * 2001-11-21 2009-12-17 Pharmacia & Upjohn Co Llc Substituierte aryl 1,4-pyrazin derivate
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CA2543644A1 (en) * 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
CN101084208A (zh) * 2004-10-22 2007-12-05 詹森药业有限公司 作为c－fms激酶抑制剂的芳族酰胺

Also Published As

Publication number Publication date
ZA200803671B (en) 2009-03-25
TW200804353A (en) 2008-01-16
MA29926B1 (fr) 2008-11-03
PE20070715A1 (es) 2007-08-11
CR9954A (es) 2008-05-28
EA200801011A1 (ru) 2009-02-27
CA2624621C (en) 2010-11-30
WO2007052123A2 (en) 2007-05-10
DOP2006000243A (es) 2007-05-31
EP1945630A2 (de) 2008-07-23
GT200600475A (es) 2007-07-06
US20070105872A1 (en) 2007-05-10
BRPI0618129A2 (pt) 2011-08-16
TNSN08196A1 (fr) 2009-10-30
NL2000284A1 (nl) 2007-05-07
NO20082496L (no) 2008-07-24
EP1945630B1 (de) 2011-09-21
JP2009514937A (ja) 2009-04-09
ECSP088412A (es) 2008-05-30
AU2006310215A1 (en) 2007-05-10
UY29893A1 (es) 2007-06-29
ES2371932T3 (es) 2012-01-11
CA2624621A1 (en) 2007-05-10
IL191059A0 (en) 2008-12-29
KR20080066073A (ko) 2008-07-15
AR057855A1 (es) 2007-12-19
US7572797B2 (en) 2009-08-11
CN101356169A (zh) 2009-01-28
WO2007052123A3 (en) 2007-07-12
AP2008004468A0 (en) 2008-06-30
NL2000284C2 (nl) 2007-09-28

Similar Documents

Publication Publication Date Title
IL191059A0 (en) Pyrazine derivatives as sodium channel modulators for the treatment of pain
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
EP2046315A4 (de) Therapeutische mittel zur behandlung maligner lymphome
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
AP2007004157A0 (en) N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
DE602005017605D1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
DE602005015442D1 (de) Kollagen-polyvinylpyrrolidon zur behandlung von osteoarthritis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties